E-resources
Peer reviewed
Open access
-
Sjöström, Martin; Zhao, Shuang G; Levy, Samuel; Zhang, Meng; Ning, Yuhong; Shrestha, Raunak; Lundberg, Arian; Herberts, Cameron; Foye, Adam; Aggarwal, Rahul; Hua, Junjie T; Li, Haolong; Bergamaschi, Anna; Maurice-Dror, Corinne; Maheshwari, Ashutosh; Chen, Sujun; Ng, Sarah W S; Ye, Wenbin; Petricca, Jessica; Fraser, Michael; Chesner, Lisa; Perry, Marc D; Moreno-Rodriguez, Thaidy; Chen, William S; Alumkal, Joshi J; Chou, Jonathan; Morgans, Alicia K; Beer, Tomasz M; Thomas, George V; Gleave, Martin; Lloyd, Paul; Phillips, Tierney; McCarthy, Erin; Haffner, Michael C; Zoubeidi, Amina; Annala, Matti; Reiter, Robert E; Rettig, Matthew B; Witte, Owen N; Fong, Lawrence; Bose, Rohit; Huang, Franklin W; Luo, Jianhua; Bjartell, Anders; Lang, Joshua M; Mahajan, Nupam P; Lara, Primo N; Evans, Christopher P; Tran, Phuoc T; Posadas, Edwin M; He, Chuan; Cui, Xiao-Long; Huang, Jiaoti; Zwart, Wilbert; Gilbert, Luke A; Maher, Christopher A; Boutros, Paul C; Chi, Kim N; Ashworth, Alan; Small, Eric J; He, Housheng H; Wyatt, Alexander W; Quigley, David A; Feng, Felix Y
Cancer research (Chicago, Ill.), 11/2022, Volume: 82, Issue: 21Journal Article
Analysis of DNA methylation is a valuable tool to understand disease progression and is increasingly being used to create diagnostic and prognostic clinical biomarkers. While conversion of cytosine to 5-methylcytosine (5mC) commonly results in transcriptional repression, further conversion to 5-hydroxymethylcytosine (5hmC) is associated with transcriptional activation. Here we perform the first study integrating whole-genome 5hmC with DNA, 5mC, and transcriptome sequencing in clinical samples of benign, localized, and advanced prostate cancer. 5hmC is shown to mark activation of cancer drivers and downstream targets. Furthermore, 5hmC sequencing revealed profoundly altered cell states throughout the disease course, characterized by increased proliferation, oncogenic signaling, dedifferentiation, and lineage plasticity to neuroendocrine and gastrointestinal lineages. Finally, 5hmC sequencing of cell-free DNA from patients with metastatic disease proved useful as a prognostic biomarker able to identify an aggressive subtype of prostate cancer using the genes TOP2A and EZH2, previously only detectable by transcriptomic analysis of solid tumor biopsies. Overall, these findings reveal that 5hmC marks epigenomic activation in prostate cancer and identify hallmarks of prostate cancer progression with potential as biomarkers of aggressive disease. In prostate cancer, 5-hydroxymethylcytosine delineates oncogene activation and stage-specific cell states and can be analyzed in liquid biopsies to detect cancer phenotypes. See related article by Wu and Attard, p. 3880.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.